Advances in medical treatment of advanced hepatobiliary and pancreatic cancer in 2022

被引：7

作者：

Zhang, Le ^{[1
]}

Liu, Rui ^{[1
]}

Deng, Ting ^{[1
]}

Ba, Yi ^{[1
,2
]}

机构：

[1] Tianjin Med Univ, Key Lab Canc Prevent & Therapy, Dept Gastrointestinal Med Oncol, Natl Clin Res Ctr Canc,Tianjins Clin Res Ctr Canc,, Tianjin, Peoples R China

[2] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Canc Ctr, Beijing, Peoples R China

来源：

CANCER INNOVATION | 2023年 / 2卷 / 01期

基金：

中国国家自然科学基金;

关键词：

hepatocellular carcinoma; biliary tract cancer; cholangiocarcinoma; pancreatic cancer; chemotherapy; targeted therapy; immunotherapy; ADVANCED HEPATOCELLULAR-CARCINOMA; BILIARY-TRACT CANCER; OPEN-LABEL; DOUBLE-BLIND; PHASE-II; 1ST-LINE TREATMENT; 2ND-LINE THERAPY; SORAFENIB; PLUS; GEMCITABINE;

D O I：

10.1002/cai2.60

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This article summarizes the drug therapy progress of advanced hepatocellular carcinoma, biliary tract cancer, and pancreatic cancer in 2022, including chemotherapy, molecular targeted therapy, and immunotherapy, to provide reference information for current clinical treatment and future clinical research, and to better improve prognosis and quality of life in patients with hepatobiliary and pancreatic cancer. Key studies in the development of systemic therapy for advanced hepatocellular carcinoma (HCC), biliary tract cancer (BTC), and pancreatic cancer. The development of immunotherapy and targeted therapy has raised the survival rate of advanced HCC to a new high. Research on targeted therapy for specific gene mutations has made great progress in precise therapy of BTC, and immunotherapy has also achieved positive results, adding new treatment options. Chemotherapy is still the main treatment for pancreatic cancer, while targeted therapy and immunotherapy have also seen some dawn in exploratory research. image

引用

页码：36 / 51

页数：16

共 72 条

[1] Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma [J].

Abou-Alfa, G. K. ;

Meyer, T. ;

Cheng, A. -L. ;

El-Khoueiry, A. B. ;

Rimassa, L. ;

Ryoo, B. -Y. ;

Cicin, I. ;

Merle, P. ;

Chen, Y. H. ;

Park, J. -W. ;

Blanc, J. -F. ;

Bolondi, L. ;

Klumpen, H. -J. ;

Chan, S. L. ;

Zagonel, V. ;

Pressiani, T. ;

Ryu, M. -H. ;

Venook, A. P. ;

Hessel, C. ;

Borgman-Hagey, A. E. ;

Schwab, G. ;

Kelley, R. K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01) :54-63

[2] Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA [J].

Abou-Alfa, Ghassan K. ;

Chan, Stephen Lam ;

Kudo, Masatoshi ;

Lau, George ;

Kelley, Robin Kate ;

Furuse, Junji ;

Sukeepaisarnjaroen, Wattana ;

Kang, Yoon-Koo ;

Dao, Tu V. ;

De Toni, Enrico N. ;

Rimassa, Lorenza ;

Breder, Valeriy Vladimirovich ;

Vasilyev, Alexander ;

Heurgue, Alexandra ;

Tam, Vincent ;

Mody, Kabir ;

Thungappa, Satheesh Chiradoni ;

He, Philip ;

Negro, Alejandra ;

Sangro, Bruno .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)

[3] Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study [J].

Abou-Alfa, Ghassan K. ;

Sahai, Vaibhav ;

Hollebecque, Antoine ;

Vaccaro, Gina ;

Melisi, Davide ;

Al-Rajabi, Raed ;

Paulson, Andrew S. ;

Borad, Mitesh J. ;

Gallinson, David ;

Murphy, Adrian G. ;

Oh, Do-Youn ;

Dotan, Efrat ;

Catenacci, Daniel, V ;

Van Cutsem, Eric ;

Ji, Tao ;

Lihou, Christine F. ;

Zhen, Huiling ;

Feliz, Luis ;

Vogel, Arndt .

LANCET ONCOLOGY, 2020, 21 (05) :671-684

[4] Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors [J].

Bahleda, Rastislav ;

Italiano, Antoine ;

Hierro, Cinta ;

Mita, Alain ;

Cervantes, Andres ;

Chan, Nancy ;

Awad, Mark ;

Calvo, Emiliano ;

Moreno, Victor ;

Govindan, Ramaswamy ;

Spira, Alexander ;

Gonzalez, Martha ;

Zhong, Bob ;

Santiago-Walker, Ademi ;

Poggesi, Italo ;

Parekh, Trilok ;

Xie, Hong ;

Infante, Jeffrey ;

Tabernero, Josep .

CLINICAL CANCER RESEARCH, 2019, 25 (16) :4888-4897

[5] Challenges and Opportunities for Pancreatic Cancer Immunotherapy [J].

Bear, Adham S. ;

Vonderheide, Robert H. ;

O'Hara, Mark H. .

CANCER CELL, 2020, 38 (06) :788-802

[6] KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation [J].

Bekaii-Saab, Tanios S. ;

Spira, Alexander I. ;

Yaeger, Rona ;

Buchschacher, Gary L. ;

McRee, Autumn Jackson ;

Sabari, Joshua K. ;

Johnson, Melissa Lynne ;

Barve, Minal A. ;

Hafez, Navid ;

Velastegui, Karen ;

Christensen, James G. ;

Kheoh, Thian ;

Der-Torossian, Hirak ;

Rybkin, Igor I. .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)

[7] Facts and Hopes in Immunotherapy of Pancreatic Cancer [J].

Bockorny, Bruno ;

Grossman, Joseph E. ;

Hidalgo, Manuel .

CLINICAL CANCER RESEARCH, 2022, 28 (21) :4606-4617

[8] Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial [J].

Bruix, Jordi ;

Qin, Shukui ;

Merle, Philippe ;

Granito, Alessandro ;

Huang, Yi-Hsiang ;

Bodoky, Gyrogy ;

Pracht, Marc ;

Yokosuka, Osamu ;

Rosmorduc, Olivier ;

Breder, Valeriy ;

Gerolami, Rene ;

Masi, Gianluca ;

Ross, Paul J. ;

Song, Tianqiang ;

Bronowicki, Jean-Pierre ;

Ollivier-Hourmand, Isabelle ;

Kudo, Masatoshi ;

Cheng, Ann-Lii ;

Llovet, Josep M. ;

Finn, Richard S. ;

LeBerre, Marie-Aude ;

Baumhauer, Annette ;

Meinhardt, Gerold ;

Han, Guohong .

LANCET, 2017, 389 (10064) :56-66

[9]

Carrato A, 2022, J CLIN ONCOL, V40

[10]

Casadei-Gardini A, 2022, J CLIN ONCOL, V40

← 1 2 3 4 5 6 7 8 →